Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
This review article focuses on the role of adenosine in coronary artery disease (CAD) diagnosis and treatment. Adenosine, an endogenous purine nucleoside, plays crucial roles in cardiovascular physiology and pathology. Its release and effects, mediated by specific receptors, influence vasomotor function, blood pressure regulation, heart rate, and platelet activity. Adenosine therapeutic effects include treatment of the no-reflow phenomenon and paroxysmal supraventricular tachycardia. The production of adenosine involves complex cellular pathways, with extracellular and intracellular synthesis mechanisms. Adenosine’s rapid metabolism underscores its short half-life and physiological turnover. Furthermore, adenosine’s involvement in side effects of antiplatelet therapy, particularly ticagrelor and cangrelor, highlights its clinical significance. Moreover, adenosine serves as a valuable tool in CAD diagnosis, aiding stress testing modalities and guiding intracoronary physiological assessments. Its use in assessing epicardial stenosis and microvascular dysfunction is pivotal for treatment decisions. Overall, understanding adenosine’s mechanisms and clinical implications is essential for optimizing CAD management strategies, encompassing both therapeutic interventions and diagnostic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986) · Circulation · doi:10.1161/01.cir.74.5.1124 · Cited by 7,812 · cited 1×
“Ischemic preconditioning is defined as a brief transient ischemia before an episode of more prolonged ischemia, which makes the myocardium more resistant to ischemia-reperfusion injury [30].”
Background2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 2×
“The incidence of dyspnea in patients treated with ticagrelor varies in different studies, from 13.8% in the PLATO trial [43] to 20% in the more recent TWILIGHT trial [44].”
BackgroundMethodInfluential2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333 · cited 3×
“The latest ESC guidelines on ACS and CCS [38,40] and many expert consensus documents support the use of coronary physiological assessment to guide PCI, in particular in angiographically intermediate coronary stenosis.”
BackgroundMethodChesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., & Ludbrook, P. (1987) · Circulation · doi:10.1161/01.cir.76.1.142 · Cited by 2,244
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001029 · Cited by 1,611
Liu, G. S., Thornton, J., Van Winkle, D. M., Stanley, A. W., Olsson, R. A., & Downey, J. M. (1991) · Circulation · doi:10.1161/01.cir.84.1.350 · Cited by 1,351 · cited 1×
“This process is thought to be mediated by endogenous adenosine through the activation of A 1 R and A 3 R [31,32].”
Backgroundvan ‘t Hof, A. W. J., Liem, A., Suryapranata, H., Hoorntje, J. C. A., de Boer, M.-J., & Zijlstra, F. (1998) · Circulation · doi:10.1161/01.cir.97.23.2302 · Cited by 1,307
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Pijls, N. H., van Son, J. A., Kirkeeide, R. L., De Bruyne, B., & Gould, K. L. (1993) · Circulation · doi:10.1161/01.cir.87.4.1354 · Cited by 1,183 · cited 1×
“Almost 30 years ago it was demonstrated that, under the condition of maximal hyperemia, the ratio of the pressure distal to the coronary stenosis to the aortic pressure was linear, and correlated with the ratio of the Doppler-derived flow velocity [73].”
Background
Cited by
John, L., Dcunha, L., Ahmed, M., Thomas, S. D., Raju, R., & Jayanandan, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-00024-3 · Cited by 20
“Moreover, Marchi et al. (2024) suggest that adenosine-related drugs, including Cangrelor, may have unintentional cardiac and neurological effects due to their impact on ATP metabolism and purinergic signaling 82 .”
Ramirez, A. Y., Doman, E. R., Sanchez, K., & CHILTON, R. J. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000332 · Cited by 12
“Its potent arterial vasodilation, however, can lead to the coronary steal phenomenon, where blood flow is diverted from ischemic regions to nonsten-otic coronary arteries [25,26].”
Adenosine receptors as emerging therapeutic targets in epilepsy
Mal’tseva, V. N., Gaidin, S. G., & Kosenkov, A. M. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0121 · Cited by 5
“Both A2A and A2B receptor activation have been shown to induce vasodilation (Marchi et al. 2024).”
Wu, J., Zhao, J., Cheng, Y., Zhou, H., Shen, G., Ding, H., Lv, J., Dong, S., & Tang, O. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06295-8 · Cited by 4
“Ade-nosine, as a product of purine metabolism, can promote vasodilation by acting on specific receptors (such as A1 and A2 receptors), thereby lowering blood pressure [35, Fig.”
Special Issue “Adenosine Receptors in Health and Disease”
Vlajkovic, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212370 · Cited by 3
“A review by Marchi et al. [7] focuses on the role of adenosine in the diagnosis and treatment of coronary artery disease (CAD).”
Metadata
- Authors
- Marchi, E., Muraca, I., Berteotti, M., Gori, A. M., Valenti, R., & Marcucci, R.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Marchi, Enrico
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 5852
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172110
- OpenAlex
- W4399092385
- Cited by
- 8
- References
- 82
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Keywords
- adenosine, coronary artery disease, adenosine receptors, no-reflow phenomenon, paroxysmal supraventricular tachycardia, adenosine metabolism, antiplatelet therapy, ticagrelor, cangrelor, stress testing, microvascular dysfunction, vasomotor function, platelet function
- MeSH terms
- Adenosine, Adenosine Monophosphate, Animals, Coronary Artery Disease, Humans, Platelet Aggregation Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease. https://app.cochat.ai/papers/10.3390/ijms25115852
- The paper
- Marchi, E., Muraca, I., Berteotti, M., Gori, A. M., Valenti, R., & Marcucci, R. (2024). Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115852
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.